On October 21, data presented at the European Society for Medical Oncology (ESMO) congress highlighted results from the STAMPEDE trial in metastatic hormone-naïve prostate cancer (mHNPCa). Although Zytiga (abiraterone) was recently approved for this subset of patients, the analysis further segmented patients into high- and low-risk subgroups, and found that all benefited from the addition of Zytiga to the standard of care. Thus, it is expected that these practice-changing results will help to combat declining revenues due to Zytiga’s impending generic erosion. The extended duration of therapy for mHNPCa makes this an expensive patient segment to treat.

According to GlobalData’s analysis, shown in Figure 1 below, the mHNPCa (represented in green) and non-metastatic castration-resistant prostate cancer (represented in pink) segments are the fastest-growing patient segments, growing at compound annual growth rates (CAGRs) of 25.7% and 21.1%, respectively, between 2016 and 2026 for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Figure 1: Prostate Cancer Sales by Patient Segment, 7MM

Source: GlobalData

Growth is mostly driven by label expansions and drug launches within the second-generation hormonal therapy category in the early to mid-forecast. J&J’s Zytiga was approved for mHNPCa in November 2017 in the EU and February 2018 in the US. An additional four approvals are expected for this patient subset before the end of the forecast period: Takeda/Myovant’s relugolix, Astellas/Pfizer’s Xtandi (enzalutamide), J&J’s Erleada (apalutamide), and Bayer/Orion’s darolutamide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.